IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Iovance reported updated Phase 2 IOV-LUN-202 results in 69 non-squamous mNSCLC patients: 24.6% overall ORR (17/69), consistent with prior 25.6%. Retrospective analysis identified biomarker-enriched subgroup (KRAS wild-type, HER2 wild-type, smoker history; 22 patients) with 59.1% ORR (13/22). Company plans sBLA submission in 2027 and launching POSITILITY, a prospective biomarker-enriched registrational-intent cohort, in November 2026.
Why this rating
Biomarker-enriched 59% ORR substantially outperforms broad 24.6% baseline, providing regulatory pathway and market focus. Represents material clinical progress for pipeline program, meaningful relative to $535M market cap, though lifilucel already approved in melanoma. Risk: retrospective subgroup findings may not prospectively replicate.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.